Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186;Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1551-1557

  Nitz, Ulrike ^a,b,c   Gluz, O ^b,c   Huober, J ^d   Kreipe, H H ^e   Kates, R E ^b   Hartmann, A ^f   Erber, R ^f   Scholz, M ^g   Lisboa, B ^h   Mohrmann, S ^a   Mobus V ⁱ   Augustin, D ^j   Hoffmann, G ^k   Weiss, E ^l   Bohmer S ^m   Kreienberg, R ⁿ   Du Bois, A ^o   Sattler, D ^p   Thomssen, C ^h   Kiechle, M ^p   Janicke F ^h   Wallwiener, D ^d   Harbeck, N ^b,q   Kuhn, W ^r   more..

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b West German Study Group   (Germany)

^c Bethesda Monchengladbach GmbH   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g TRIUM ANALYSIS ONLINE GMBH   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ Staedtisches Klinikum   (Germany)

^j Clinics Deggendorf Mammacenter Ostbayern   (Germany)

^k ST JOSEFS HOSPITAL   (Germany)

^l Women's Clinic Kreiskrankenhaus Boeblingen   (Germany)

^m Department of Obstetrics and Gynecology Ev Hospital Oberhausen   (Germany)

ⁿ UNIVERSITY HOSPITAL ULM   (Germany)

^o DR HORST SCHMIDT KLINIKEN   (Germany)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^q UNIVERSITY OF MUNICH   (Germany)

^r UNIVERSITY HOSPITAL BONN   (Germany)

more..

Author keywords

Adjuvant chemotherapy; Luminal A B like subtypes; Node positive breast cancer; Overtreatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; TRASTUZUMAB; HORMONE RECEPTOR; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADULT; AGED; AMENORRHEA; ANEMIA; ANTIGEN EXPRESSION; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY CANCER; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; FOLLOW UP; HUMAN TISSUE; INTERMEDIATE RISK PATIENT; NEUROPATHY; POLYNEUROPATHY; PROTEIN EXPRESSION; ADJUVANT CHEMOTHERAPY; ADOLESCENT; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84905187179     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw349     Document Type: Erratum

References (21)

1. Henderson I, Berry D, Demtri G et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
2. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel- carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
3. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
4. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
5. Penault-Llorca F, Andre F, Sagan C et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2809-2815.
6. Arbeitsgemeinschaft Gynäkologische Onkologie E.V. Aktuelle Empfehlungen zur Diagnostik und Therapie primärer und metastasierter Mammakarzinome der Kommission MAMMA in der AGO e.V. www.ago-online.de 2006. Version 6.1.0, Oktober 2006.
7. Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. The Lancet 2012; 379: 432-444.
8. Janni W, Harbeck N, Sommer HL et al. AGO-Study Group. Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study. J Clin Oncol (Meeting Abstracts) 2010; 28: 535.
9. Ellis P, Barrett-Lee P, Johnson L et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. The Lancet 2009; 373: 1681-1692.
10. Burnell M, Levine MN, Chapman J-AW et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in nodepositive or high-risk node-negative breast cancer. J Clin Oncol 2010; 28: 77-82.
11. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006; 24: 5664-5671.
12. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. New Engl J Med 2008; 358: 1663-1671.
13. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C 9741/ Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
14. Swain SM, Tang G, Geyer CE et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, nodepositive breast cancer: the NSABP B-38 trial. J Clin Oncol 2013; 31: 3197-3204.
15. Eiermann W, Pienkowski T, Crown J et al. Phase III study of doxorubicin/ cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, nodepositive breast cancer: BCIRG-005 trial. J Clin Oncol 2011; 29: 3877-3884.
16. Mackey JR, Martin M, Pienkowski T et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013; 14: 72-80.
17. Karp J, Blackford A, Visvanathan K et al. Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. Cancer Res 2012; 72: S3-S5.
18. Rutgers E, Piccart-Gebhart MJ, Bogaerts J et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011; 47: 2742-2749.
19. Luporsi E, André F, Spyratos F et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132: 895-915.
20. Oakman C, Francis PA, Crown J et al. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol 2013; 24: 1203-1211.
21. Martín M, Rodríguez-Lescure Á, Ruiz A et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010; 123: 149-157.